{"filings":[{"id":777916,"accession_number":"0001628280-26-039461","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2026-06-01T20:07:27+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"GRAIL appoints Joshua Ofman as CEO with amended compensation and severance","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Joshua Ofman appointed CEO effective June 1, 2026; annual base salary $800,000.","Variable Compensation Plan target increased to 100% of base salary from prior 60%.","New RSU award of $2,000,000 vesting over four years granted.","Severance: 24 months salary + 200% bonus in change of control; 12 months + 100% bonus outside.","Company posted investor slide presentation on May 31, 2026 (content not detailed in filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94794,"accession_number":"0001628280-26-030495","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q1 2026: revenue $40.8M (up 28%), Galleri volume 56k+ (up 50%), net loss $93.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $40.8M (+28% YoY); Galleri revenue $39.8M (+37%); test volume >56,000 (+50%).","Net loss $93.2M, improved $13.0M (12%) vs Q1 2025; adjusted EBITDA $(79.9)M, improved 19%.","Adjusted gross profit $19.7M (+38% YoY); cash & equivalents $823.1M.","Plans to integrate Galleri into Epic EHR; new NHS-Galleri and PATHFINDER 2 data at ASCO 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":40785000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107414,"accession_number":"0001699031-26-000009","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"NHS-Galleri trial misses primary endpoint but shows Stage IV reduction; Q4 rev $43.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint of significant Stage III-IV reduction not met; substantial Stage IV reduction observed across 12 deadly cancers.","Adding Galleri to standard care yielded four-fold higher cancer detection rate and increased Stage I-II detection of deadly cancers.","Q4 total revenue $43.6M (+14% YoY); US Galleri revenue $41.3M (+31% YoY). Full year revenue $147.2M (+17% YoY).","Net loss Q4 $99.2M (incl. $34.6M amort.); full year net loss $408.4M (incl. $138.3M amort. and $28M impairment).","Galleri PMA submitted to FDA; U.S. sales force to expand based on NHS-Galleri and PATHFINDER 2 results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107413,"accession_number":"0001628280-26-001786","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL to present preliminary Q4/FY2025 results at JP Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 2026 J.P. Morgan Healthcare Conference on January 12, 2026.","No specific financial figures provided in the filing or exhibit snippet.","Preliminary results for quarter and year ended December 31, 2025; details unavailable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123763,"accession_number":"0001628280-25-052184","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRAIL enters $300M ATM equity distribution agreement with Morgan Stanley and TD Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $300M of common stock (max 6.9M shares) at-the-market.","Sales agents (Morgan Stanley, TD Securities) will receive 3.0% commission on gross proceeds.","Also filed prospectus for resale of 3.9M shares (1.93M common + 1.99M pre-funded warrant shares) from Oct 2025 purchase.","ATM proceeds intended for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123762,"accession_number":"0001699031-25-000189","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q3 revenue $36.2M (+26% YoY); U.S. Galleri revenue $32.6M (+28%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $89.0M, improving 29% YoY; adjusted EBITDA $(71.7)M.","Galleri tests sold >45,000, up 39% YoY; PMA submission to FDA expected Q1 2026.","Cash $547.1M at Sep 30; pro forma >$850M after private placement.","Non-GAAP adjusted gross profit $20.0M (+69% YoY); gross loss $13.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":103575000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123761,"accession_number":"0001628280-25-045532","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GRAIL raises $325M in private placement at $70.05/share; funds operations into 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$325M from 4,639,543 shares/pre-funded warrants at $70.05/share.","Investors include Deep Track Capital, Farallon, Hims & Hers, Braidwell, and three life sciences firms.","Proceeds to fund commercial activities, reimbursement efforts, and general corporate purposes.","Company expects funding to support planned operations into 2030, excluding Samsung's $110M investment.","Private placement expected to close Oct 21, 2025; registration rights granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123760,"accession_number":"0001628280-25-045239","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Samsung invests $110M in GRAIL at $70.05/sh; exclusive Galleri rights in South Korea; Q3 prelim results","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Samsung C&T and Samsung Electronics invest $110M in GRAIL at $70.05/share (~1.57M shares) via private placement.","GRAIL grants Samsung C&T exclusive rights to commercialize Galleri MCED test in South Korea, with possible expansion to Japan and Singapore.","Closing expected early 2026, subject to CFIUS clearance, definitive collaboration agreements, and other conditions.","Preliminary Q3 2025: total revenue $35.7-36.7M, US screening revenue $32.1-33.1M, operating loss $123.9-126.9M.","Cash and marketable securities as of Sep 30, 2025: ~$547M; proceeds to support commercialization and reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140447,"accession_number":"0001699031-25-000180","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"GRAIL signs 11-year lease for 75,556 RSF Sunnyvale HQ; base rent ~$449,558/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11-year lease for ~75,556 RSF office/lab at 250 S. Matilda Ave, Sunnyvale, CA.","Lease starts Oct 1, 2026; expires Sep 30, 2037; base rent starts at $5.39M/yr (~$5.95/RSF) escalating ~5% annually.","Tenant improvement allowance of $14.36M ($190/RSF) plus $3.02M ($40/RSF) additional allowance.","Landlord requires a $3.625M letter of credit as security.","Tenant has option to expand into additional space and renew for five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140446,"accession_number":"0001699031-25-000162","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q2 revenue $35.5M (+11% YoY); net loss $114M includes $28M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. Galleri revenue $34.2M (+21% YoY); Galleri tests sold >45,000 (+29% YoY).","Non-GAAP adjusted EBITDA $(78.3)M, improving 44% YoY from $(139.4)M.","Cash and marketable securities $606.1M as of June 30, 2025.","PATHFINDER 2 detailed results to be submitted for presentation at ESMO 2025 in October."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":67381000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158126,"accession_number":"0001699031-25-000122","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRAIL stockholders elect William Chase as Class I director; ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["William Chase elected with 19.0M votes for, 1.2M withheld, and 9.4M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025: 29.1M for, 66.9K against, 529.9K abstentions.","Annual Meeting held May 29, 2025; quorum of 29.7M shares out of 35.3M entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158125,"accession_number":"0001699031-25-000120","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GRAIL amends offer letters for President and CFO, enhancing severance benefits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Josh Ofman annual base salary remains $655,000; Aaron Freidin base salary $560,000; target bonus unchanged at 50% of base.","Severance in CIC termination: 12 months base salary + 100% target bonus + full equity acceleration + 12 months COBRA.","Severance in non-CIC termination: 12 months base salary + 100% target bonus + 12 months equity acceleration + COBRA.","Amended letters maintain indemnification rights and D&O insurance coverage; agreements supersede prior offer letters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158124,"accession_number":"0001699031-25-000110","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q1 revenue $31.8M (+19% YoY); Galleri U.S. revenue $28.7M (+22%); net loss improves","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $31.8M, up 19% YoY; U.S. Galleri revenue $28.7M, up 22% YoY.","Net loss $106.2M, improvement of $112.7M or 51% YoY; adjusted EBITDA -$98.7M.","Positive top-line results from NHS-Galleri trial; cash $677.9M provides runway into 2028.","Over 37,000 Galleri tests completed in Q1 2025; company focused on cost efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":31837000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176496,"accession_number":"0001699031-25-000016","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q4 rev $38.3M (+26%), net loss $97.1M; FY Galleri rev $108.6M (+45%); adds TRICARE coverage","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $38.3M (+26% YoY); Q4 Galleri revenue $31.6M (+39% YoY).","Full year 2024 total revenue $125.6M (+35% YoY); Galleri revenue $108.6M (+45% YoY).","Q4 net loss $97.1M including $34.6M amortization; full year net loss $2.0B incl $1.4B goodwill impairment.","Non-GAAP adjusted EBITDA: Q4 ($84.0M), full year ($483.5M); cash position $767M, runway into 2028.","TRICARE added Galleri as covered benefit for 50+ patients; registrational studies completed, PMA submission planned H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-63.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":125595000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176495,"accession_number":"0001628280-25-001580","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL presents preliminary Q4/FY2024 financial update at JPMorgan conference; specific figures not in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Corporate update and preliminary Q4 and FY2024 financial results presented at J.P. Morgan Healthcare Conference on Jan 15, 2025.","Presentation furnished as Exhibit 99.1, but detailed financial figures are not provided in the filing text excerpt available.","CEO Bob Ragusa presented; full presentation may contain revenue, EPS, and other key metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":-63.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":125595000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193350,"accession_number":"0001628280-24-047100","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q3 2024: Galleri revenue $25.4M (+52% YoY); net loss $(125.7)M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $28.7M (+38% YoY); Galleri revenue $25.4M (+52% YoY).","Net loss $(125.7)M includes $34.6M amortization and $19.0M restructuring charge.","Non-GAAP adjusted EBITDA $(108.2)M, improved 14% YoY; adjusted gross profit $11.8M.","Cash $853.6M, runway into 2028; commercial Galleri tests surpassed 250,000 since launch.","CEO Bob Ragusa highlighted cost management and progress toward FDA PMA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":-61.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":87343000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193349,"accession_number":"0001628280-24-043305","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GRAIL appoints Sarah Krevans to Board of Directors, effective Oct 21","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Krevans appointed as Class II director; will serve on Audit, Compensation, and Nominating & Governance Committees.","Receives annual cash retainer of $50,000 plus committee retainers ($10k Audit, $7.5k Comp, $5k NCG), and initial grant of 31,055 RSUs vesting over 3 years.","Krevans previously President and CEO of Sutter Health; Board now has 5 directors, 4 independent.","Company disclosed ~$1.6M in 2023 payments to Sutter Institute for Medical Research for PATHFINDER 2 study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209697,"accession_number":"0001628280-24-036944","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRAIL Q2 revenue up 43% to $32M; net loss $(1.59)B due to $1.42B impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $32.0M (+43% YoY), driven by Galleri test sales exceeding 215,000 cumulative units.","Net loss of $(1.59)B includes $1.42B goodwill and intangible impairment; adjusted EBITDA loss $(139.4)M.","Adjusted gross profit of $16.0M (66% YoY improvement); gross loss improved to $(17.9)M.","Cash and equivalents $958.8M; portfolio prioritization and restructure extend cash runway into 2028.","First quarterly results as independent public company after separation from Illumina on June 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-58.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":58691000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209696,"accession_number":"0001628280-24-035247","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"GRAIL Q2 results included in Illumina earnings; standalone report due Aug 13","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Illumina announced Q2 2024 results including GRAIL's operations through June 24, 2024 separation date.","GRAIL was one of Illumina's two reportable segments for the period before the separation.","GRAIL will report its own complete Q2 2024 financial results on Tuesday, August 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209695,"accession_number":"0001628280-24-030858","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K/A","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GRAIL converts pre-spin awards to 6.6M RSUs; sets 2024 Plan share limit at 8.66M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash-based equity awards converted to 6,589,187 RSUs under 2024 Plan based on VWAP over four days post-Distribution.","Initial 2024 Plan share reserve: 8,656,817 shares (23% of fully diluted shares post-spin), inclusive of converted RSUs.","ESPP initial share reserve: 414,021 shares (1.1% of fully diluted shares post-spin).","Non-employee Director annual compensation capped at $750,000 ($1,000,000 in initial year or lead director year).","All awards granted under 2024 Plan and ESPP effective as of June 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227827,"accession_number":"0001628280-24-030355","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["2.06"],"status":"ready","headline":"GRAIL expects $888.9M goodwill impairment & ~$420M IPR&D charge in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Goodwill impairment charge of $888.9 million, full remaining carrying value as of March 31, 2024.","IPR&D intangible impairment estimated at ~$420 million pushed down from Illumina's spin-off.","Total IPR&D intangible assets were $560.0 million as of March 31, 2024.","No material future cash expenditures expected from these impairments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227826,"accession_number":"0001193125-24-167037","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","3.03","5.03","5.01","5.02","9.01"],"status":"ready","headline":"GRAIL completes spin-off from Illumina; receives $932M funding, starts trading June 25","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Illumina distributed 85.5% of GRAIL shares to its shareholders (1 per 6 shares) on June 24, 2024; Illumina retains 14.5%.","GRAIL received ~$932.3M one-time disposal funding from Illumina; begins trading on Nasdaq under GRAL on June 25.","New board of four directors appointed: Bill Chase, Steve Mizell, Greg Summe (Chair), Robert Ragusa; Ragusa named CEO, Freidin CFO.","GRAIL converted from LLC to corporation; adopted new certificate of incorporation, bylaws, equity plans, and indemnification agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227830,"accession_number":"0001193125-24-159261","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GRAIL LLC names three directors, including Illumina CFO and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective June 11, 2024, Illumina (sole member) established GRAIL's board of directors.","Charles Dadswell (Illumina General Counsel) appointed chair of board and all three committees.","Ankur Dhingra (Illumina CFO) appointed director; neither he nor Dadswell will receive GRAIL compensation.","William Chase appointed independent director; will receive non-employee director compensation and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227828,"accession_number":"0001193125-24-155278","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K/A","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GRAIL distribution date June 24; when-issued trading June 12-24, regular-way June 25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution effective 12:01 AM ET on June 24, 2024, as a pro rata dividend of at least 85.5% of GRAIL shares from Illumina.","GRAIL common stock to trade when-issued on Nasdaq under GRALV from about June 12 through the distribution date.","Regular-way trading under symbol GRAL expected to begin June 25, 2024, the first trading day after distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227829,"accession_number":"0001193125-24-153238","cik":1699031,"company_name":"GRAIL, Inc.","ticker":"GRAL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRAIL spin-off from Illumina declared effective; distribution details set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SEC declared effective Form 10 for GRAIL spin-off on June 3, 2024.","Spin-off effective June 24, 2024; Illumina holders receive 1 GRAIL share per 6 ILMN shares held on June 13 record date.","GRAIL common stock to trade regular way on Nasdaq under 'GRAL' starting June 25, 2024.","Prior to spin-off, GRAIL LLC converts to Delaware corporation, renamed GRAIL, Inc.","Distribution subject to satisfaction or waiver of conditions in Information Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3274750732.4355226,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}